Peer‑Reviewed Study Confirms ABL Diagnostics’ CE‑IVD Whole‑Genome HIV‑1 Assay as a Global First
Independent clinical validation strengthens ABL’s leadership in the fast‑growing HIV drug‑resistance testing market ABL Diagnostics SA (EPA:ABLD – ISIN : FR001400AHX6) WOIPPY, MOSELLE, FRANCE, March 11, 2026 /EINPresswire.com/ -- ABL …